|
|||||
|
|
Overview and update on molecular testing in non-small cell lung carcinoma utilizing endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples |
|
| Authors: | María Jesús Fernández Aceñero MD PhD Cristina Díaz del Arco CDdA MD Carme Dinarés CD MD PhD Tania Labiano TL MD Eva Tejerina ET MD PhD Mª José Bernabé MJ B MD Elena Forcen EF MD Melchor Saiz-Pardo MSP MD Pablo Pérez PP MD Maria D Lozano MDL MD PhD |
| Institution: | 1. Departments of Surgical Pathology, Hospital Clínico San Carlos, Madrid, Spain;2. Department of Surgical Pathology, Valld'Hebron, Barcelona, Spain;3. Department of Surgical Pathology, Clínica Universitaria of Navarra, Pamplona, Spain;4. Department of Surgical Pathology, Clínica Puerta de Hierro, Madrid, Spain;5. Department of Pneumology, Hospital Clínico San Carlos, Madrid, Spain |
| Abstract: | Lung carcinoma remains one of the most frequent and aggressive human neoplasms. Fortunately, in the last decades, the increasing knowledge of the molecular mechanisms leading to cancer development has allowed the use of targeted therapies with improvement of prognosis in many patients. Clinical management has also changed after the introduction of endobronchialultrasonographic bronchoscopy that allows a conservative staging of lung tumors, avoiding the need of mediastinoscopy for lymph node staging. Lung pathologists and cytopathologists are facing the challenge of giving the more comprehensive prognostic and predictive information with ever smaller tissue or cytological samples. The aim of this review is to summarize the molecular testing for non-small cell lung carcinoma and how pathologists can contribute to the patient's outcome with a conscious management of biological samples. |
| Keywords: | endobronchial ultrasonographic broncoscopy molecular pathology non-small cell lung carcinoma targeted therapies |